Buy Rating on Context Therapeutics's CTIM-76 Bolstered by Market Validation and Competitive Edge

TipRanksApr 12 01:15

Context Therapeutics Submitted An FDA Investigational New Drug To Begin Phase 1 Dose Escalation And Expansion Trial Of CTIM-76 For Claudin 6-Positive Gynecologic And Testicular Cancers

Context Therapeutics Submitted An FDA Investigational New Drug To Begin Phase 1 Dose Escalation And Expansion Trial Of CTIM-76 For Claudin 6-Positive Gynecologic And Testicular Cancers

BenzingaApr 1 19:46

Context Therapeutics Advances Cancer Trial With FDA Submission

TipRanksApr 1 19:42

Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers

Important Regulatory Milestone Supports Next Phase of CTIM-76 DevelopmentPHILADELPHIA, April 01, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (Nasdaq: CNTX), a bio

GlobeNewswireApr 1 19:30

Buy Rating Justified by Advances in T Cell Engagers and Context Therapeutics' Strategic Drug Positioning

TipRanksMar 23 01:55

Context Therapeutics Price Target Cut to $4.00/Share From $5.00 by HC Wainwright & Co.

Context Therapeutics Price Target Cut to $4.00/Share From $5.00 by HC Wainwright & Co.

Dow JonesMar 22 00:31